NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Stempoint Capital LP

Stempoint Capital LP boosted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 147.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 180,658 shares of the company’s stock after buying an additional 107,552 shares during the quarter. Stempoint Capital LP’s holdings in NewAmsterdam Pharma were worth $5,783,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in NewAmsterdam Pharma in the 1st quarter valued at about $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of NewAmsterdam Pharma by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock worth $5,898,000 after purchasing an additional 34,563 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of NewAmsterdam Pharma by 15.9% in the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after purchasing an additional 13,629 shares in the last quarter. Legal & General Group Plc lifted its stake in NewAmsterdam Pharma by 33.5% during the second quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock valued at $801,000 after purchasing an additional 11,106 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in NewAmsterdam Pharma by 12.7% during the second quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock worth $2,427,000 after buying an additional 15,101 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 210,000 shares of company stock worth $6,713,550. Insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $27.91 on Thursday. The company has a 50-day moving average of $32.45 and a two-hundred day moving average of $32.73. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of -15.59 and a beta of 0.08. NewAmsterdam Pharma Company N.V. has a one year low of $21.14 and a one year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Jefferies Financial Group reissued a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Finally, BMO Capital Markets began coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.42.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.